Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Andros Pharmaceuticals Co (ROCO:6917) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Andros Pharmaceuticals Co had a gross margin of 32.79% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Andros Pharmaceuticals Co Gross Margin % Related Terms
Andros Pharmaceuticals Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6917 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Andros Pharmaceuticals Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Andros Pharmaceuticals Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Andros Pharmaceuticals Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Andros Pharmaceuticals Co (ROCO:6917) has a Gross Margin % of 32.79% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Andros Pharmaceuticals Co and its competitors. This is 31% below median its historical median of 47.64. Over the past decade, Andros Pharmaceuticals Co's Gross Margin % has ranged from 4.93 to 72.71. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #549 out of 732 companies in the Biotechnology industry, placing it in the top 75%.
Is Andros Pharmaceuticals Co's Gross Margin % too high?
Andros Pharmaceuticals Co's current Gross Margin % of 32.79% is 31% below median its 10-year median of 47.64. Over the past 10 years, this metric has ranged from a low of 4.93 to a high of 72.71. The Biotechnology industry median Gross Margin % is 60.91. Andros Pharmaceuticals Co's value of 32.79% is 46.2% below this industry median. Based on the distribution chart, Andros Pharmaceuticals Co ranks #549 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #549 out of 732 companies for Gross Margin %. This places Andros Pharmaceuticals Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Andros Pharmaceuticals Co's value of 32.79% is 46.2% below this benchmark. Historically, Andros Pharmaceuticals Co's own Gross Margin % has ranged from 4.93 to 72.71 over the past decade. While the company's 10-year median is 47.64 vs. the industry median of 60.91, Andros Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Andros Pharmaceuticals Co's current Gross Margin % of 32.79% is 46.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Andros Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Andros Pharmaceuticals Co's current Gross Margin % is 32.79%, which is 31% below median its own 10-year median of 47.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.02, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current Gross Margin % is 32.79%, which is 31% below median its 10-year median of 47.64 and 46.2% below the Biotechnology industry median of 60.91. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Gross Margin % is 32.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02.
GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6917:
Gross Margin %: 32.79% (31% below median its 10-year median of 47.64)
GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
Industry Position: 46.2% below the Biotechnology median (#549 of 732)
No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score
Get the complete analysis for ROCO:6917
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6917 has been successfully added to your 
